A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma

被引：17

作者：

Hermanson, David L. ^{[1
]}

Barnett, Burton Earle ^{[1
]}

Rengarajan, Srinivas ^{[1
]}

Codde, Rebecca ^{[1
]}

Wang, Xinxin ^{[1
]}

Tan, Yening ^{[1
]}

Martin, Christopher E. ^{[1
]}

Smith, Jenessa Barbara ^{[1
]}

He, Jin ^{[2
]}

Mathur, Rohit ^{[3
]}

Yan, Jing

Neelapu, Sattva S. ^{[4
]}

Osertag, Eric M. ^{[1
]}

Shedlock, Devon J. ^{[1
]}

机构：

[1] Poseida Therapeut, San Diego, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.2127.2127

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2127

引用

页数：5

共 50 条

[1] PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic exhibits improved potency and durability
Hermanson, David
Barnett, Burton E.
Rengarajan, Srinivas
Codde, Rebecca
Martin, Christopher E.
Wang, Xinxin
Tan, Yening
Smith, Jenessa B.
He, Jin
Mathur, Rohit
Neelapu, Sattva S.
Yang, Jing
Ostertag, Eric M.
Devon, Shedlock J.
CANCER RESEARCH, 2017, 77
[2] Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2
Liu, Rui
Yang, Rui
Xu, Xuezhu
Zhao, Wanhong
Wang, Fangxia
Zhang, Wanggang
Lei, Bo
Yang, Ruoyu
Wang, Yiwen
He, Aili
Wang, Jianli
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (05) : 1780 - 1789
[3] DIRECTED IMMUNOTHERAPY: CAR-T STUDY AGAINST BCMA FOR THE TREATMENT OF MULTIPLE MYELOMA
Perez Amill, L.
Sune, G.
Castella, M.
Urbano Ispizua, A.
Martin Antonio, B.
HAEMATOLOGICA, 2017, 102 : 52 - 52
[4] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
Yao, Xin
Zhu, Shigui
Huang, Jiaqi
Qu, Xiaoyan
Zhu, Judy
Wei, Yutian
Lan, Liping
Lv, Xiaoteng
Wu, Junfeng
Wang, Rirfei
Yang, Dingzhu
Zheng, Chengxiao
Zhao, DiJun
Fan, Lei
Huang, Fei
Lu, Hua
Zhang, Chaocan
Chen, Cheng
Li, Yanfeng
Ren, Jiaqiang
Zhang, Li
Humphries, Michael
Li, Jianyong
Yao, Yihong
BLOOD, 2019, 134
[5] BCMA-SPECIFIC TAC RECEPTOR-ENGINEERED T CELLS FOR MULTIPLE MYELOMA
Bezverbnaya, K.
Lau, V.
Aarts, C.
Denisova, G.
Afsahi, A.
Cummings, D.
Helsen, C. W.
Bramson, J.
CYTOTHERAPY, 2018, 20 (05) : S9 - S9
[6] CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
Berahovich, Robert
Zhou, Hua
Xu, Shirley
Wei, Yuehua
Guan, Jasper
Guan, Jian
Harto, Hizkia
Fu, Shuxiang
Yang, Kaihuai
Zhu, Shuying
Li, Le
Wu, Lijun
Golubovskaya, Vita
CANCERS, 2018, 10 (09)
[7] Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma
Saldarriaga, Mateo Mejia
Pan, Darren
Unkenholz, Caitlin
Mouhieddine, Tarek
Fein, Josh
Monge, Jorge
Rosenbaum, Cara
Pearse, Roger
Jayabalan, David
Gordillo, Christian
Chan, Hei Ton
Mapara, Markus
Inghirami, Giorgio
Lentzsch, Suzanne
Reshef, Ren
Rossi, Adriana
Parekh, Samir
Jagannath, Sundar
Richards, Shambavi
Niesvizky, Ruben
Bustoros, Mark
CANCER RESEARCH, 2024, 84 (06)
[8] γ-SECRETASE INHIBITORS IMPROVE MULTIPLE MYELOMA BCMA CAR-T THERAPY
不详
CANCER DISCOVERY, 2019, 9 (11) : 1483 - 1483
[9] Efficacy and safety of BCMA-specific CAR T cell-based therapy in relapsed/refractory multiple myeloma patients with extramedullary disease
Qi, Yue Kun
Li, Zhenyu
Xu, Kailin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S57 - S57
[10] Efficacy and Safety of BCMA-Specific CAR T Cell-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients with Extramedullary Disease
Qi, Yuekun
Qiao, Jianlin
Li, Zhenyu
Xu, Kailin
BLOOD, 2023, 142

← 1 2 3 4 5 →